Funtleyder Leslie D. 4

What Happened

• Leslie D. Funtleyder, Interim Chief Executive Officer and Chief Financial Officer of Applied Therapeutics (APLT), reported dispositions tied to the company’s merger. She disposed of a total of 2,782,151 common-equivalent shares (including shares and derivative awards) in connection with the merger.
• The consideration was $0.088 per share in cash (about $244,829 total) plus one non-tradeable contingent value right (CVR) per share, per the Merger Agreement. The filings show an earlier compensatory grant of 1,187,500 restricted stock units (RSUs) on 2025-12-19 that vested/converted under the merger terms.

Key Details

• Transaction dates: RSU grant on 2025-12-19; merger effective 2026-01-28; Form 4 filed 2026-02-03.
• Price/consideration: $0.088 per share in cash plus a CVR; cash proceeds ≈ $244,829.
• Breakdown (as reported): 2,375,000 shares tendered to the issuer; 152,959 shares disposed in change of control; ~254,192 shares from derivative awards/options converted/cancelled.
• Shares owned after transaction: All outstanding common shares and RSUs were canceled/converted at the effective time of the merger; common shares were converted into the merger consideration.
• Notable footnotes: RSUs were compensatory awards that vested upon a Change in Control; all outstanding RSUs/options were treated per the Merger Agreement (vested and converted or, if out‑of‑the‑money, cancelled).
• Filing: Form 4 filed on Feb 3, 2026 reporting these merger-related dispositions (effective at the merger’s Jan 28, 2026 Effective Time).

Context

• These transactions are merger-related conversions/cancellations (dispositions to the issuer), not open-market sales; the insider received the negotiated merger consideration (cash + CVR). For retail investors, merger conversions typically reflect deal terms rather than a direct trading decision by the insider.